Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.60 |
| ▸ | NAMPT | P43490 | 18/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14316368 | 0.89 | GPR119 (0.60) | GPR119NAMPTCYP2C9 | |
| SCHEMBL15203186 | 0.86 | GPR119 (0.57) | GPR119NAMPTCYP2C9 | |
| SCHEMBL14316367 | 0.86 | GPR119 (0.57) | GPR119NAMPTCYP2C9 | |
| SCHEMBL20077751 | 0.86 | GPR119 (0.57) | GPR119NAMPTCYP2C9 | |
| SCHEMBL30451669 | 0.86 | GPR119 (0.57) | GPR119NAMPTCYP2C9 | |
| SCHEMBL8044737 | 0.83 | GPR119 (0.54) | GPR119NAMPTCYP2C9 | |
| SCHEMBL21644282 | 0.83 | GPR119 (0.54) | GPR119NAMPTCYP2C9 | |
| SCHEMBL21644082 | 0.83 | GPR119 (0.54) | GPR119NAMPTCYP2C9 | |
| SCHEMBL20077298 | 0.83 | GPR119 (0.54) | GPR119NAMPTCYP2C9 | |
| SCHEMBL20068583 | 0.82 | GPR119 (0.52) | GPR119NAMPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME LLC (US) | 2023-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, NR1H4 | GPR119 15/4885NAMPT 4040/4885CYP2C9 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.